Please assess the completion status of the following clinical trial:

Trial Title: The Use of Nicotine Patches Together With E-cigarettes (With and Without Nicotine) for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke and want to quit in the next three months~* Reside in New Zealand~* At least 18 years of age~* Able to provide verbal consent~* Have access to telephone (mobile and/or landline)~* Are prepared to use a nicotine patch or a nicotine patch and e-cigarette together.~* Only one person per household is eligible.~Exclusion Criteria:~* Pregnant women~* Women who are breastfeeding~* Current users of NRT products~* People currently enrolled in another smoking cessation programme or other cessation study~* People who have used an e-cigarette for more than one week in the last year for smoking cessation~* Current users of non-nicotine based cessation therapies (e.g. buproprion, clonidine, nortriptyline or varenicline).~* People who have had a heart attack, stroke or severe angina within the previous two weeks.~* People who self-report a history of severe allergies and/or poorly controlled asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patch (Type: ACTIVE_COMPARATOR): 21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
- Patch and nicotine-free e-cigarette (Type: ACTIVE_COMPARATOR): 21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
- Patch and nicotine e-cigarette (Type: ACTIVE_COMPARATOR): 21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit

Based on this trial design, predict the completion outcome and termination type (if applicable).